content: <html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:cah="http://cardinalhealth.com/20220905" xmlns="http://www.w3.org/1999/xhtml">
    <head>
      <title></title>
      <!-- Licensed to: Wachtell, Lipton, Rosen & Katz
           Document created using Broadridge PROfile 22.7.2.5063
           Copyright 1995 - 2022 Broadridge -->
      <meta http-equiv="Content-Type" content="text/html" />
  </head>
  
  <body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
  <div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_190409351da945fbbe65eee91acf4ccf" contextRef="c20220905to20220905" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_6a706bd7defc4405b0f6133a87afad33" contextRef="c20220905to20220905">0000721371</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="cah-20220905.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20220905to20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  
    <!--PROfilePageNumberReset%Num%1%%%-->
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">
      <div style="text-align: left;">
        <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>
  <div>
      UNITED STATES</div>
  </div>
  
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
  
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>
  
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">
      <hr style="height: inherit; width: 20%; color: #000000; background-color: #000000;" /></div>
  
    <div style="text-align: center; margin-top: 3pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_fd6830dfec8d466d94d6582d40d505b6" contextRef="c20220905to20220905">8-K</ix:nonNumeric>
      <br />
    </div>
  
    <div style="text-align: center; margin-top: 3pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">
      <hr style="height: inherit; width: 20%; color: #000000; background-color: #000000;" /> </div>
  
    <div style="text-align: center; margin-top: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">CURRENT REPORT</div>
  
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the<span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br />
      </span>Securities Exchange Act of 1934</div>
  
    <div style="text-align: center; margin-top: 6pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Date of Report (Date of earliest event reported):&#160; <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_8a316df863124678b5c83739c0585773" contextRef="c20220905to20220905" format="ixt:datemonthdayyearen">September 5, 2022</ix:nonNumeric></div>
  
    <div style="text-align: left; margin-top: 6pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">
      <hr style="height: inherit; width: 20%; color: #000000; background-color: #000000;" /></div>
  
    <div style="text-align: center; margin-top: 12pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 24pt;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_3df6f15f9bd74631b2d31c4c6ebb6171" contextRef="c20220905to20220905">Cardinal Health, Inc.</ix:nonNumeric></span><br />
      (Exact name of registrant as specified in its charter)<br />
    </div>
  
    <div style="text-align: center; margin-top: 12pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
      <hr style="height: inherit; width: 20%; color: #000000; background-color: #000000;" /></div>
  
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  
  
    <tr>
  
      <td style="width: 32.1%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_c3b1d169ef414924b552b71fe310aa6c" contextRef="c20220905to20220905" format="ixt-sec:stateprovnameen">Ohio</ix:nonNumeric><br />
            </div>
          </td>
  
      <td style="width: 1.02%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
  
      <td style="width: 32.92%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_2b284246a74a425383214deff041088f" contextRef="c20220905to20220905">1-11373</ix:nonNumeric><br />
            </div>
          </td>
  
      <td style="width: 1.02%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
  
      <td style="width: 32.94%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_b311b2c4ae6c440ba28c85adeebaff6c" contextRef="c20220905to20220905">31-0958666</ix:nonNumeric><br />
            </div>
          </td>
  
    </tr>
  
    <tr>
  
      <td style="width: 32.1%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">(State or Other Jurisdiction</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">of Incorporation)</div>
          </td>
  
      <td style="width: 1.02%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
          </td>
  
      <td style="width: 32.92%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">(Commission</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">File Number)</div>
          </td>
  
      <td style="width: 1.02%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
          </td>
  
      <td style="width: 32.94%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">(IRS Employer</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">Identification No.)</div>
          </td>
  
    </tr>
  
  
  </table>
    <div><br />
    </div>
  
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  
  
    <tr>
  
      <td style="width: 100%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br />
            </div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_3436f610b82a4d8abdfd0e826a4ea1a3" contextRef="c20220905to20220905">7000 Cardinal Place</ix:nonNumeric>,
              <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_4d6b55d1e8a041f98e71cc4e7f36a307" contextRef="c20220905to20220905">Dublin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_9aa7cb6ccba443469b38ecf4c6c9ee85" contextRef="c20220905to20220905" format="ixt-sec:stateprovnameen">Ohio</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_e0e5bf1a14194858af05ae9a3c41077d" contextRef="c20220905to20220905">43017</ix:nonNumeric></div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">(Address of Principal Executive Offices) (Zip Code)</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> <br />
            </div>
          </td>
  
    </tr>
  
    <tr>
  
      <td style="width: 100%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_4b357bf6dfbe41538e65aece1b403146" contextRef="c20220905to20220905">614</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_db9da761cb6841249ee987c40852f164" contextRef="c20220905to20220905">757-5000</ix:nonNumeric></div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">(Registrant&#8217;s telephone number, including area code)</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> <br />
            </div>
          </td>
  
    </tr>
  
  
  </table>
    <div>
      <div style="margin-bottom: 12pt;">
        <hr style="height: inherit; width: 20%; color: #000000; background-color: #000000;" /></div>
  
      <div style="text-align: left; margin-bottom: 3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of
        the following provisions <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(see General Instruction A.2. below):</span></div>
  
    </div>
  
    <div style="text-align: left; margin-bottom: 3pt; text-indent: -9pt; margin-left: 9pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_dc4667a2c441463ba5cba63cacedd55a" contextRef="c20220905to20220905" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  
    <div style="text-align: left; margin-bottom: 3pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_9011cd45df8f4d2b9f38cc3c690471b1" contextRef="c20220905to20220905" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160; Soliciting
        material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  
    <div style="text-align: left; margin-bottom: 3pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_a486052835e54f8a938d1265b80704e8" contextRef="c20220905to20220905" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;&#160;&#160;&#160;
        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  
    <div style="text-align: left; margin-bottom: 6pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_0bb0e6c2250c4c8c8a585c6c8df538b4" contextRef="c20220905to20220905" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;&#160;&#160;&#160;
        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>
  
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
    </div>
  
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  
  
    <tr>
  
      <td style="width: 36.61%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title of each class</div>
          </td>
  
      <td style="width: 39.1%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Trading Symbol(s)</div>
          </td>
  
      <td style="width: 24.3%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Name of each exchange on which registered</div>
          </td>
  
    </tr>
  
    <tr>
  
      <td style="width: 36.61%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_8335989fbb8c44b89d720c1f59ea144d" contextRef="c20220905to20220905">Common shares (without par value)</ix:nonNumeric><br />
            </div>
          </td>
  
      <td style="width: 39.1%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_23c697ef21c34b9f8f3b6020f745b3e3" contextRef="c20220905to20220905">CAH</ix:nonNumeric><br />
            </div>
          </td>
  
      <td style="width: 24.3%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_134357ea92c44f139950700ff0dcadf9" contextRef="c20220905to20220905" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric><br />
            </div>
          </td>
  
    </tr>
  
  
  </table>
    <div style="text-align: left; margin-top: 6pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
      1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>
  
    <div style="text-align: right; margin-bottom: 6pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_b58c59e76f0b42e6a1276c685540f93d" contextRef="c20220905to20220905" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>
  
    <div style="text-align: left; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
      with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#9744;</span></div>
  
    <div style="text-align: left; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
  <div><br /></div>
  
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>
  
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; font-size: 12pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
  
    </div>
  
    <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 1.01.&#160; Entry into a Material Definitive Agreement.</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On September 5, 2022, Cardinal Health, Inc. (the &#8220;Company&#8221;) entered into a Cooperation Agreement (the &#8220;Cooperation
      Agreement&#8221;) with Elliott Associates, L.P. and Elliott International, L.P. (together, &#8220;Elliott&#8221;). The Cooperation Agreement will remain effective until the later of (i) July 15, 2023 and (ii) 11:59&#160;p.m., Eastern Time, on the date that is five days
      following the date on which the Investor Designee (as defined below) or the Investor Designee&#8217;s successor ceases to serve on, or resigns from, the Company&#8217;s board of directors (the &#8220;Board&#8221;).</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the Cooperation Agreement, the Company agreed, among other things, to appoint Steven K. Barg, Global Head of
      Engagement at Elliott (the &#8220;Investor Designee&#8221;), Michelle M. Brennan, Sujatha Chandrasekaran and Christine A. Mundkur as new independent members of the Board (collectively with the Investor Designee, the &#8220;New Directors&#8221;), effective as of September 6,
      2022. Each of the New Directors will be nominated by the Board to stand for election for a full term at the 2022 Annual Meeting of Shareholders (the &#8220;2022 Annual Meeting&#8221;). Following the departure of two directors (as discussed under Item 5.02 below),
      the size of the Board will be automatically decreased to 13 directors at the conclusion of the 2022 Annual Meeting.</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In connection with the appointment of the New Directors, the Company also established an advisory Business Review
      Committee (the &#8220;Business Review Committee&#8221;) to address the matters contemplated by the Cooperation Agreement and the charter of the Business Review Committee. The Committee has three members: Jason M. Hollar, the Business Review Committee&#8217;s chair and
      the Chief Executive Officer of the Company, the Investor Designee and Akhil Johri. The Business Review Committee, with the assistance of the Company&#8217;s legal and financial advisors, will make recommendations to the full Board.</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the Cooperation Agreement, Elliott has agreed to abide by certain standstill restrictions and voting
      commitments. The Cooperation Agreement also includes procedures regarding the replacement of any of the New Directors prior to the 2023 Annual Meeting of Shareholders and a mutual non-disparagement provision.</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company&#8217;s obligations with respect to, among other things, the appointment of the New Directors, the nomination of
      the New Directors for election at the 2022 Annual Meeting, the replacement of a New Director upon departure from the Board and the formation of the Business Review Committee fall away in certain circumstances, including if Elliott has a net long
      position in the Company of less than 2.25%.</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The foregoing summary of the Cooperation Agreement does not purport to be complete and is qualified in its entirety by
      reference to the full text of the Cooperation Agreement, including the initial Business Review Committee charter attached as an exhibit to the Cooperation Agreement, a copy of which is attached as Exhibit 10.1 and is incorporated by reference.</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
    </div>
  
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="DSPFPageNumber">2</span></div>
  
      <div style="page-break-after: always;" class="DSPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>
  
    </div>
  
    <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 5.02.&#160; Departure of Directors or Certain Officers&#894; Election of Directors&#894; Appointment of Certain Officers&#894;
      Compensatory Arrangements of Certain Officers.</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information set forth in Item 1.01 is incorporated herein by reference.</div>
  
    <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Director Appointments</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the Cooperation Agreement, each of the New Directors was appointed to the Board effective September 6, 2022.
      The Board has affirmatively determined that each of the New Directors is &#8220;independent&#8221; under the rules of the New York Stock Exchange and the rules and regulations of the U.S. Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Each of the New Directors will receive compensation consistent with that received by the Company&#8217;s other non-employee
      directors, as described in the Company&#8217;s proxy statement on Schedule 14A for the 2021 Annual Meeting, filed with the U.S. Securities and Exchange Commission on September 23, 2021.</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">There are no arrangements or understandings between any of the New Directors and any other person pursuant to which any
      of the New Directors was appointed as a director other than with respect to the matters referred to in Item 1.01. At this time, there are no transactions in which any of the New Directors has or will have an interest that would be required to be
      disclosed pursuant to Item 404(a) of Regulation S-K under the Exchange Act.</div>
  
    <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Committee Composition</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effective as of September 6, 2022, the Board has reconstituted the Board&#8217;s standing committees as follows:</div>
  
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  
  
    <tr>
  
      <td style="width: 21.05%; vertical-align: top;">
            <div>&#160;</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">Audit Committee</span></div>
          </td>
  
      <td style="width: 30.7%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
            </div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">Governance and Sustainability Committee</span></div>
          </td>
  
      <td style="width: 25.44%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;"> <br />
              </span></div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">Human Resources and Compensation Committee</span></div>
          </td>
  
      <td style="width: 22.81%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
            </div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">Risk Oversight Committee</span></div>
          </td>
  
    </tr>
  
    <tr>
  
      <td style="width: 21.05%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akhil Johri (Chair)</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Michelle M. Brennan</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sujatha Chandrasekaran</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sheri H. Edison</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">David C. Evans</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">John H. Weiland</div>
          </td>
  
      <td style="width: 30.7%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patricia A. Hemingway Hall (Chair)</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Steven K. Barg</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carrie S. Cox</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Bruce L. Downey</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gregory B. Kenny</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nancy Killefer</div>
          </td>
  
      <td style="width: 25.44%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carrie S. Cox (Chair)</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Michelle M. Brennan</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patricia A. Hemingway Hall</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nancy Killefer</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Christine A. Mundkur</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dean A. Scarborough</div>
          </td>
  
      <td style="width: 22.81%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sheri H. Edison (Chair)</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sujatha Chandrasekaran</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Bruce L. Downey</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">David C. Evans</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Christine A. Mundkur</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dean A. Scarborough</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">John H. Weiland</div>
          </td>
  
    </tr>
  
  
  </table>
    <div style="margin-bottom: 12pt;"><br />
    </div>
  
    <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Directors Not Standing for Re-election</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On September 6, 2022, the Company announced that Dean A. Scarborough and John H. Weiland have expressed their intent not
      to stand for re-election at the 2022 Annual Meeting.&#160; <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Messrs. Scarborough and Weiland will continue to serve as directors until the 2022 Annual Meeting.&#160; </span>The
      decisions of Messrs. Scarborough and Weiland were not due to any disagreements relating to matters concerning the Company&#8217;s operations, policies or practices, and the Board is greatly appreciative of Messrs. Scarborough&#8217;s and Weiland&#8217;s service and
      substantial contributions.</div>
  
    <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.01.&#160; Regulation FD Disclosure.</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On September 6, 2022, the Company issued a news release announcing the Company&#8217;s entry into the Cooperation Agreement
      and the matters described in Item 1.01 and Item 5.02.&#160; A copy of the news release is attached as Exhibit 99.1.</div>
  
    <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01.&#160; Financial Statements and Exhibits.</div>
  
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; margin-bottom: 12pt;">
  
  
    <tr>
  
      <td style="width: 27pt;"><br />
          </td>
  
      <td style="width: 27pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)</td>
  
      <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exhibits</div>
          </td>
  
    </tr>
  
  
  </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  
  
    <tr>
  
      <td style="width: 14.42%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit No.</div>
            </div>
          </td>
  
      <td style="width: 85.58%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
            </div>
          </td>
  
    </tr>
  
    <tr>
  
      <td style="width: 14.42%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit10-1.htm">10.1</a></div>
          </td>
  
      <td style="width: 85.58%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cooperation Agreement, dated as of September 5, 2022, by and among Cardinal Health, Inc., Elliott Associates, L.P. and Elliott International, L.P.</div>
          </td>
  
    </tr>
  
    <tr>
  
      <td style="width: 14.42%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit99-1pressrelease.htm">99.1</a></div>
          </td>
  
      <td style="width: 85.58%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">News release issued by the Company on September 6, 2022 announcing governance enhancements and shareholder value creation initiatives.</div>
          </td>
  
    </tr>
  
    <tr>
  
      <td style="width: 14.42%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
          </td>
  
      <td style="width: 85.58%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
          </td>
  
    </tr>
  
  
  </table>
    <div><br />
    </div>
  
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; font-size: 12pt;" class="DSPFPageBreakArea">
      <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="DSPFPageNumber">3</span></div>
  
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
  
    </div>
  
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>
  
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 24pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
      signed on its behalf by the undersigned hereunto duly authorized.</div>
  
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  
  
    <tr>
  
      <td style="width: 50.5%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date:&#160; September&#160;6, 2022</div>
          </td>
  
      <td style="width: 49.5%; vertical-align: top;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cardinal Health, Inc.</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Registrant)</div>
          </td>
  
    </tr>
  
    <tr>
  
      <td style="width: 50.5%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
  
      <td style="width: 4.04%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
  
      <td style="width: 45.46%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
  
    </tr>
  
    <tr>
  
      <td style="width: 50.5%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
          </td>
  
      <td style="width: 4.04%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
          </td>
  
      <td style="width: 45.46%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Jessica L. Mayer</div>
          </td>
  
    </tr>
  
    <tr>
  
      <td style="width: 50.5%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
          </td>
  
      <td style="width: 4.04%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
          </td>
  
      <td style="width: 45.46%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name: Jessica L. Mayer</div>
          </td>
  
    </tr>
  
    <tr>
  
      <td style="width: 50.5%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
          </td>
  
      <td style="width: 4.04%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
          </td>
  
      <td style="width: 45.46%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title:&#160;&#160; Chief Legal and Compliance Officer</div>
          </td>
  
    </tr>
  
  
  </table>
    <div><br />
    </div>
  
    <div style="text-align: center; font-size: 12pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="DSPFPageNumber">4</span></div>
  
  </body>
  </html>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "22-9-6cah8k.htm", "secsgml_size_bytes": 39750}]
metadata_filer: {"company-data": {"conformed-name": "CARDINAL HEALTH INC", "cik": "0000721371", "assigned-sic": "5122", "irs-number": "310958666", "state-of-incorporation": "OH", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11373", "film-number": "221226825"}, "business-address": {"street1": "7000 CARDINAL PLACE", "city": "DUBLIN", "state": "OH", "zip": "43017", "phone": "6147573033"}, "mail-address": {"street1": "7000 CARDINAL PLACE", "city": "DUBLIN", "state": "OH", "zip": "43017"}, "former-company": {"former-conformed-name": "CARDINAL DISTRIBUTION INC", "date-changed": "19920703"}}
text: UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM
  8-K
  CURRENT REPORT
  Pursuant to Section 13 or 15(d) of the
  Securities Exchange Act of 1934
  Date of Report (Date of earliest event reported):
  September 5, 2022
  Cardinal Health, Inc.
  (Exact name of registrant as specified in its charter)
  Ohio
  1-11373
  31-0958666
  (State or Other Jurisdiction
  of Incorporation)
  (Commission
  File Number)
  (IRS Employer
  Identification No.)
  7000 Cardinal Place
  ,
  Dublin
  ,
  Ohio
  43017
  (Address of Principal Executive Offices) (Zip Code)
  (
  614
  )
  757-5000
  (Registrant's telephone number, including area code)
  Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of
        the following provisions
  (see General Instruction A.2. below):
  ☐
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  ☐
  Soliciting
        material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  ☐
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  ☐
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
  Securities registered pursuant to Section 12(b) of the Act:
  Title of each class
  Trading Symbol(s)
  Name of each exchange on which registered
  Common shares (without par value)
  CAH
  New York Stock Exchange
  Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
      1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
  Emerging growth company
  ☐
  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
      with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
  ☐
  Item 1.01.  Entry into a Material Definitive Agreement.
  On September 5, 2022, Cardinal Health, Inc. (the "Company") entered into a Cooperation Agreement (the "Cooperation
      Agreement") with Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott"). The Cooperation Agreement will remain effective until the later of (i) July 15, 2023 and (ii) 11:59 p.m., Eastern Time, on the date that is five days
      following the date on which the Investor Designee (as defined below) or the Investor Designee's successor ceases to serve on, or resigns from, the Company's board of directors (the "Board").
  Pursuant to the Cooperation Agreement, the Company agreed, among other things, to appoint Steven K. Barg, Global Head of
      Engagement at Elliott (the "Investor Designee"), Michelle M. Brennan, Sujatha Chandrasekaran and Christine A. Mundkur as new independent members of the Board (collectively with the Investor Designee, the "New Directors"), effective as of September 6,
      2022. Each of the New Directors will be nominated by the Board to stand for election for a full term at the 2022 Annual Meeting of Shareholders (the "2022 Annual Meeting"). Following the departure of two directors (as discussed under Item 5.02 below),
      the size of the Board will be automatically decreased to 13 directors at the conclusion of the 2022 Annual Meeting.
  In connection with the appointment of the New Directors, the Company also established an advisory Business Review
      Committee (the "Business Review Committee") to address the matters contemplated by the Cooperation Agreement and the charter of the Business Review Committee. The Committee has three members: Jason M. Hollar, the Business Review Committee's chair and
      the Chief Executive Officer of the Company, the Investor Designee and Akhil Johri. The Business Review Committee, with the assistance of the Company's legal and financial advisors, will make recommendations to the full Board.
  Pursuant to the Cooperation Agreement, Elliott has agreed to abide by certain standstill restrictions and voting
      commitments. The Cooperation Agreement also includes procedures regarding the replacement of any of the New Directors prior to the 2023 Annual Meeting of Shareholders and a mutual non-disparagement provision.
  The Company's obligations with respect to, among other things, the appointment of the New Directors, the nomination of
      the New Directors for election at the 2022 Annual Meeting, the replacement of a New Director upon departure from the Board and the formation of the Business Review Committee fall away in certain circumstances, including if Elliott has a net long
      position in the Company of less than 2.25%.
  The foregoing summary of the Cooperation Agreement does not purport to be complete and is qualified in its entirety by
      reference to the full text of the Cooperation Agreement, including the initial Business Review Committee charter attached as an exhibit to the Cooperation Agreement, a copy of which is attached as Exhibit 10.1 and is incorporated by reference.
  2
  Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
      Compensatory Arrangements of Certain Officers.
  The information set forth in Item 1.01 is incorporated herein by reference.
  Director Appointments
  Pursuant to the Cooperation Agreement, each of the New Directors was appointed to the Board effective September 6, 2022.
      The Board has affirmatively determined that each of the New Directors is "independent" under the rules of the New York Stock Exchange and the rules and regulations of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").
  Each of the New Directors will receive compensation consistent with that received by the Company's other non-employee
      directors, as described in the Company's proxy statement on Schedule 14A for the 2021 Annual Meeting, filed with the U.S. Securities and Exchange Commission on September 23, 2021.
  There are no arrangements or understandings between any of the New Directors and any other person pursuant to which any
      of the New Directors was appointed as a director other than with respect to the matters referred to in Item 1.01. At this time, there are no transactions in which any of the New Directors has or will have an interest that would be required to be
      disclosed pursuant to Item 404(a) of Regulation S-K under the Exchange Act.
  Committee Composition
  Effective as of September 6, 2022, the Board has reconstituted the Board's standing committees as follows:
  Audit Committee
  Governance and Sustainability Committee
  Human Resources and Compensation Committee
  Risk Oversight Committee
  Akhil Johri (Chair)
  Michelle M. Brennan
  Sujatha Chandrasekaran
  Sheri H. Edison
  David C. Evans
  John H. Weiland
  Patricia A. Hemingway Hall (Chair)
  Steven K. Barg
  Carrie S. Cox
  Bruce L. Downey
  Gregory B. Kenny
  Nancy Killefer
  Carrie S. Cox (Chair)
  Michelle M. Brennan
  Patricia A. Hemingway Hall
  Nancy Killefer
  Christine A. Mundkur
  Dean A. Scarborough
  Sheri H. Edison (Chair)
  Sujatha Chandrasekaran
  Bruce L. Downey
  David C. Evans
  Christine A. Mundkur
  Dean A. Scarborough
  John H. Weiland
  Directors Not Standing for Re-election
  On September 6, 2022, the Company announced that Dean A. Scarborough and John H. Weiland have expressed their intent not
      to stand for re-election at the 2022 Annual Meeting.
  Messrs. Scarborough and Weiland will continue to serve as directors until the 2022 Annual Meeting.
  The
      decisions of Messrs. Scarborough and Weiland were not due to any disagreements relating to matters concerning the Company's operations, policies or practices, and the Board is greatly appreciative of Messrs. Scarborough's and Weiland's service and
      substantial contributions.
  Item 7.01.  Regulation FD Disclosure.
  On September 6, 2022, the Company issued a news release announcing the Company's entry into the Cooperation Agreement
      and the matters described in Item 1.01 and Item 5.02.  A copy of the news release is attached as Exhibit 99.1.
  Item 9.01.  Financial Statements and Exhibits.
  (d)
  Exhibits
  Exhibit No.
  Description
  10.1
  Cooperation Agreement, dated as of September 5, 2022, by and among Cardinal Health, Inc., Elliott Associates, L.P. and Elliott International, L.P.
  99.1
  News release issued by the Company on September 6, 2022 announcing governance enhancements and shareholder value creation initiatives.
  104
  Cover Page Interactive Data File (embedded within the Inline XBRL document)
  3
  SIGNATURE
  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
      signed on its behalf by the undersigned hereunto duly authorized.
  Date:  September 6, 2022
  Cardinal Health, Inc.
  (Registrant)
  By:
  /s/ Jessica L. Mayer
  Name: Jessica L. Mayer
  Title:   Chief Legal and Compliance Officer
  4